All Hands In

Campaign Urging Research for Eosinophilic Disease

Education, Research, Advocacy, Awareness and Funding for EGID Research

a

The CURED Mission

CURED is a not for profit foundation dedicated to those suffering from Eosinophilic Gastrointestinal Diseases (EGID), including eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic colitis (EC), and other eosinophilic disorders.

CURED is committed to raising substantial funding to aid in research, advocating on behalf of EGID patients and their families and working to educate and increase awareness about this complex group of diseases. It is our heartfelt belief that CURED can make a difference for the individuals and their families who are touched by these diseases.

We are proud to endorse American Gastroenterological Association
#Freston2021 virtual!

Solidarity Statement

Recent tragic events affecting communities across America unfortunately highlight hate, discrimination, and inequities facing black lives. CURED Foundation joins in solidarity with those seeking justice and systemic change. Only when we achieve equal justice and opportunity for all people - no matter their race, ethnicity, national origin, creed, gender, and sexual orientation - can we live in a peaceful and fair world.

CURED’s mission seeks better medical treatment and to advance research of eosinophilic diseases, which are rare and not well understood. In keeping with our mission, we also recognize that many people of color face additional barriers impacting access to health care including for rare medical conditions. Inherent discrimination prevents many patients from being accurately diagnosed or diagnosed at all. Standing up to racism means standing up to barriers inherent in health care so that we can achieve better quality of life for everyone.

COVID -19 & EGIDS

Fast Facts About COVID -19 & EGIDs From Dr. Marc Rothenburg

  • We do not have substantial data about COVID-19 and EGID.

  • We do know that EGID is not an immune-deficiency disease.

  • There is no known risk for viral infections in EGID patients.

  • Patients on eosinophil depleting drugs such as benralizumab and patients with eosinophilia have not been reported to have an increased risk of viral infections and/or complications from viral infections, indicating that eosinophil dysregulation (increased or decreased levels) is not a primary response against viruses.

  • Fluticasone and Budesonide are not systemic steroid medications, and therefore there’s no immune suppression.

covid image

A caveat to this information concerns rare EGID patients that may have another underlying disease or EGID patients on systemic steroids; these patients may have some increased risk for complications. Such patients should consult with their primary doctor for specific advice and guidance.
Patients with concerns should contact their health provider on a case by case basis. This is still a very fluid situation.
Also check https://www.cdc.gov/ and https://www.who.int/

In view of the evolving COVID-19 infection, we advise patients and their families to follow the CDC’s recommendations for travel, preventative measures, and preparedness at www.cdc.gov. Stay updated with your state and local health department’s advisories for your area.

provided by CURED Medical Advisory Board Member
Marc E. Rothenberg MD, PhD
Professor of Pediatrics
Bunning Chair of Allergy and Immunology
Director, Division of Allergy and Immunology
Director, Cincinnati Center for Eosinophilic Disorders
Cincinnati Children’s Hospital Medical Center